StockNews.AI
NTRA
StockNews.AI
104 days

Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows

1. Natera's Prospera Heart shows improved allograft rejection detection capabilities. 2. The study's publication may enhance NTRA's market credibility and adoption.

2m saved
Insight
Article

FAQ

Why Bullish?

The clinical validation of Prospera Heart can drive revenue growth, similar to past innovations.

How important is it?

Positive study outcomes can lead to increased interest and trust in Natera's products.

Why Short Term?

Immediate investor sentiment may improve with new study results influencing short-term stock performance.

Related Companies

AGNILMNPACB
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the American Journal of Transplantation (AJT) published a new study1 evaluating the performance of Prospera Heart with DQS to detect allograft rejection. Prospera with DQS leverages a two-threshold algorithm, combining the traditional donor fraction (dd-cfDNA %, measuring dd-cfDNA as a fraction of total cfDNA) and donor quantity score (DQS, estimating the to.

Related News